← Sino Medical Sciences Technology In overview

Sino Medical Sciences Technology In vs Guangzhou Wondfo Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Sino Medical Sciences Technology In (688108.CG)

Q3 2026
▲4

Sino Medical's profit surge and overseas approvals drive the story

  • First-half profit jumps on coronary and neuro product sales Sino Medical said first-half 2026 net profit should rise about 264% to 50.3 million yuan, as its coronary products sold more and new neuro products grew strongly, with revenue up about 27% and costs controlled. That profit growth is the main force pushing the stock up.

    This is the core earnings driver behind the period's move.

  • Interim report confirms the profit jump and healthy cash flow The actual interim report matched the forecast: 305 million yuan revenue, 50.3 million yuan net profit, and 94 million yuan of cash coming in from operations. A low debt ratio and 70% gross margin show the business is profitable and not stretched, supporting the shares.

    It confirms the earnings surprise with real numbers and cash flow.

  • Overseas approvals open new markets for heart devices Sino Medical won registration for its coronary balloon catheter in Vietnam and Colombia, letting it sell these heart products in those countries. Each approval is a small but real step in overseas expansion, adding future sales that support the stock price.

    New market approvals are a fresh growth path for the company.

  • H-share listing plan and Paraguay stent approval add capital and reach Sino Medical is filing to issue H-shares in Hong Kong, expected to finish early next year, which could raise new money. Its HT Supreme drug-eluting stent also won approval in Paraguay. Both broaden funding and sales, though the H-share plan is still pending.

    It shows a new funding route and another overseas market.

August 2026
▲4

Sino Medical's profit surge and overseas approvals drive the story

  • First-half profit jumps on coronary and neuro product sales Sino Medical said first-half 2026 net profit should rise about 264% to 50.3 million yuan, as its coronary products sold more and new neuro products grew strongly, with revenue up about 27% and costs controlled. That profit growth is the main force pushing the stock up.

    This is the core earnings driver behind the period's move.

  • Interim report confirms the profit jump and healthy cash flow The actual interim report matched the forecast: 305 million yuan revenue, 50.3 million yuan net profit, and 94 million yuan of cash coming in from operations. A low debt ratio and 70% gross margin show the business is profitable and not stretched, supporting the shares.

    It confirms the earnings surprise with real numbers and cash flow.

  • Overseas approvals open new markets for heart devices Sino Medical won registration for its coronary balloon catheter in Vietnam and Colombia, letting it sell these heart products in those countries. Each approval is a small but real step in overseas expansion, adding future sales that support the stock price.

    New market approvals are a fresh growth path for the company.

  • H-share listing plan and Paraguay stent approval add capital and reach Sino Medical is filing to issue H-shares in Hong Kong, expected to finish early next year, which could raise new money. Its HT Supreme drug-eluting stent also won approval in Paraguay. Both broaden funding and sales, though the H-share plan is still pending.

    It shows a new funding route and another overseas market.

Latest
▲4

Sino Medical's profit surge and overseas approvals drive the story

  • First-half profit jumps on coronary and neuro product sales Sino Medical said first-half 2026 net profit should rise about 264% to 50.3 million yuan, as its coronary products sold more and new neuro products grew strongly, with revenue up about 27% and costs controlled. That profit growth is the main force pushing the stock up.

    This is the core earnings driver behind the period's move.

  • Interim report confirms the profit jump and healthy cash flow The actual interim report matched the forecast: 305 million yuan revenue, 50.3 million yuan net profit, and 94 million yuan of cash coming in from operations. A low debt ratio and 70% gross margin show the business is profitable and not stretched, supporting the shares.

    It confirms the earnings surprise with real numbers and cash flow.

  • Overseas approvals open new markets for heart devices Sino Medical won registration for its coronary balloon catheter in Vietnam and Colombia, letting it sell these heart products in those countries. Each approval is a small but real step in overseas expansion, adding future sales that support the stock price.

    New market approvals are a fresh growth path for the company.

  • H-share listing plan and Paraguay stent approval add capital and reach Sino Medical is filing to issue H-shares in Hong Kong, expected to finish early next year, which could raise new money. Its HT Supreme drug-eluting stent also won approval in Paraguay. Both broaden funding and sales, though the H-share plan is still pending.

    It shows a new funding route and another overseas market.

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Q3 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

August 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

Latest
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.